HealthcareServices

Soft Tissue Sarcoma Market Growth Projection: Expected to Surpass $5.17 Billion by 2030 at 8.7% CAGR

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the soft tissue sarcoma market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Soft Tissue Sarcoma Market size between 2026 and 2035?

The soft tissue sarcoma market has shown robust expansion in recent years. This market is forecast to increase from $3.41 billion in 2025 to $3.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.4%. The historical rise in this market can be linked to factors like enhanced cancer diagnostics, financial support for oncology research, heightened awareness of rare cancers, the accessibility of chemotherapy, and developments in surgical procedures.

The market for soft tissue sarcoma is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $5.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. Key drivers for this growth during the projection period encompass the approval of new drugs, the broader application of immunotherapy, an increase in molecular testing, the rising need for personalized treatments, and advancements in oncology infrastructure. Noteworthy trends expected over the forecast horizon involve the increased adoption of targeted therapies, more extensive genetic profiling, the development of more combination regimens, a rise in participation in clinical trials, and the integration of multidisciplinary care approaches.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12211&type=smp

Which Drivers Are Impacting Market Performance In The Soft Tissue Sarcoma Market?

An anticipated rise in cancer cases is projected to fuel the expansion of the soft tissue sarcoma market in the coming period. Cancer encompasses a wide range of diseases, originating in any bodily organ or tissue, characterized by the unchecked multiplication of abnormal cells that extend beyond their normal limits, either metastasizing to distant organs or infiltrating adjacent tissues. This growing occurrence of cancer necessitates more diagnostic interventions, various treatment options, and comprehensive supportive care services designed to address the specific needs of individuals afflicted with different forms of cancer or sarcoma, thereby stimulating the market for soft tissue sarcomas. For example, data released in July 2024 by the Australian Institute of Health and Welfare, an Australian government body, indicated that approximately 165,000 Australians received a new cancer diagnosis in 2023, translating to more than 450 new cases daily, with males accounting for roughly 55% of these diagnoses. Consequently, the escalating incidence of cancer is a key factor propelling the growth of the soft tissue sarcoma market.

What Segment Types Are Examined In The Soft Tissue Sarcoma Market?

The soft tissue sarcoma market covered in this report is segmented –

1) By Treatment: Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Other Treatments

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

3) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies, Immunotherapy Agents

2) By Chemotherapy: Doxorubicin, Ifosfamide, Gemcitabine, Other Chemotherapeutic Agents

3) By Anti-Angiogenesis Drugs: Bevacizumab, Pazopanib, Axitinib, Other Anti-Angiogenesis Agents

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy

5) By Other Treatments: Surgery, Clinical Trials, Supportive Care

Which Innovation Trends Are Advancing Developments Within The Soft Tissue Sarcoma Market?

Leading companies within the soft tissue sarcoma market are focusing on developing innovative products to enhance their market standing. For instance, in November 2023, Mercy, a US-based not-for-profit Catholic healthcare organization, launched an inventive AI-driven texting program named The Chen Chemotherapy Model to proactively prevent hospitalizations linked to chemotherapy. This program utilizes a smart texting platform that sends daily messages to chemotherapy patients seven days a week, excluding weekends and holidays. The texts offer a list of symptoms, including diarrhea, pain, fever, fatigue, nausea or vomiting, or no symptoms. Patients can select and rate their symptoms, and based on their responses, the information may be escalated to their healthcare provider. The aim is to identify potential issues promptly and intervene before symptoms deteriorate, showcasing Mercy’s dedication to utilizing technology for improved patient care in the domain of chemotherapy.

Who Are The Major Companies Operating In The Soft Tissue Sarcoma Market?

Major companies operating in the soft tissue sarcoma market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Philogen S.p.A., Taiho Pharmaceutical Co.Ltd., Nanobiotix S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/soft-tissue-sarcoma-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Soft Tissue Sarcoma Market?

North America was the largest region in the soft tissue sarcoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the soft tissue sarcoma market report during the forecast period. The regions covered in the soft tissue sarcoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Soft Tissue Sarcoma Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12211&type=smp

Browse Through More Reports Similar to the Global Soft Tissue Sarcoma Market 2026, By The Business Research Company

Soft Tissue Repair Market Report 2026

https://www.thebusinessresearchcompany.com/report/soft-tissue-repair-global-market-report

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Central Nervous System Lymphoma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-lymphoma-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795